By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    Balance Work & Life: Working Hours Tracker Can Prevent Burnout
    February 29, 2024
    car accident
    6 Tips for Faster Car Accident Recovery
    May 27, 2024
    The Impact of Virtual Healthcare Assistants on Clinical Practices
    August 1, 2024
    Latest News
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
    Chewing Matters More Than You Think: Why Proper Chewing Supports Better Health
    May 22, 2025
    Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
    May 16, 2025
    Learn how to Renew your Medical Card in West Virginia
    May 16, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Year-End Health Policy Musings
    December 25, 2011
    Engage With Grace
    November 22, 2012
    State of Virginia Attaches Amendment to Bill Requiring Women to Have an Ultrasound Before an Abortion That Requires Men to Have A Rectal Exam Before Obtaining A Prescription For Erectile Dysfunction Drugs
    January 31, 2012
    Latest News
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
    The Critical Role of Healthcare in Personal Injury Recovery: A Comprehensive Guide for Victims
    May 14, 2025
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”
Medical InnovationsSpecialtiesTechnology

Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”

Deanna Pogorelc
Last updated: December 6, 2013 9:00 am
Deanna Pogorelc
Share
4 Min Read
chemotherapy
SHARE

chemotherapyFirst published on MedCityNews.com. Efforts to overcome the unusual ability of cancer cells to dodge the body’s immune response have reached an inflection point this year.

chemotherapyFirst published on MedCityNews.com. Efforts to overcome the unusual ability of cancer cells to dodge the body’s immune response have reached an inflection point this year. And, at least according to some experts, commercial interest in cancer immunotherapies has gone through the roof.

“If you had asked most Big Pharmas in the beginning of 2013 if they were interested in immunotherapy, they would have said ‘not necessary, we’re (more) in small molecules,’” explained Marc Mansour, chief operating officer of Canadian vaccine developer Immunovaccine, in an interview last month.

But by the end of the American Society of Clinical Oncology’s annual conference this summer, the sentiment had shifted. Both Bristol-Myers Squibb and Merck presented solid early-stage data on their respective PD-1 inhibitors that added to excitement that’s been building over the past several years around immunotherapy.

More Read

Could Orphan Drugs Turn Health Economics on its Ear?
Hooray for High-Priced Hepatitis Treatment Sovaldi
Laser Eye Surgery Or Implantable Contact Lenses: Which Is Right For You?
Enhance FO Operational Efficiency In Healthcare And BI Reports
Sustainable Tips For Financial Management In Medical Practice

Since then, AstraZeneca, for one, has added to its cancer portfolio of small molecule drugs and biologics with a $500 million buyout of Amplimmune in August. Bayer also signed an agreement with Compugen to research, develop and commercialize immunotherapies. Then there’s Roche, which signed deals with Inovio Pharmaceuticals and Germany’s immatics.

Both Bristol-Myers Squibb and Merck’s candidates are PD-1 inhibitors, which fall under an especially promising class of drugs being called immune checkpoint inhibitors.

“At least five or six pharmaceutical companies are conducting clinical trials on checkpoint inhibitors, and I think that we’re going to see approvals probably in the next year or two,” said Dr. James Gulley, director of medical oncology services at the National Cancer Institute’s Center for Cancer Research.

Bristol-Myers Squibb’s Yervoy, FDA approved in 2011 for treatment of melanoma, was the first checkpoint inhibitor on the market. A second generation of drugs in this area seem to be better tolerated but induce just as much immune activity, he said.

The real potential, though, lies in the ability of these inhibitors to be combined with other kinds of drugs, like vaccines. Gulley explained that vaccines – like the ones being developed my Immunovaccine, Merck, GSK and others – would act as the “gas” and the “steering” that would turn on the immune system and set its aim to fight cancerous cells. Then the checkpoint inhibitors would disable the “brake” – the body’s tendency to turn off the immune response once it’s killed the infected cells.

“Combination therapy is the way of the future,” Immunovaccine’s Mansour reiterated. For an upcoming phase 2 clinical trial in brain cancer, the company is pairing its vaccine candidate with temozolomide, an immune modulator that’s the standard therapy for newly diagnosed gliobastoma patients after surgery and radiation.

“But, it can’t be a $100K therapy on top of another $100K therapy,” he added. That’s one of the big industry takeaways from Dendreon’s Provenge, the first immunotherapy to be approved by the FDA back in 2010. The therapy, which requires a patient’s immune cells to be sent to a lab where they’re reprogrammed to attack cancer cells, and then sent back and injected back into the patient, has been met with weak sales that have forced the drugmaker to restructure.

“That’s not sustainable,” Mansour summed up. “We have to push to find therapies that work, and you have to think about it as a therapy rather than a compound.”

[Image credit: Flickr user Phil and Pam]

TAGGED:cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

stress impact your health
The Hidden Impact Of Stress On Your Body’s Alignment And Balance
Health Wellness
May 22, 2025
chewing better for health
Chewing Matters More Than You Think: Why Proper Chewing Supports Better Health
Dental health Health
May 22, 2025
Do You Grind Your Teeth at Night? Here’s How Night Guards and TMJ Treatments Can Help
Do You Grind Your Teeth at Night? Here’s How Night Guards and TMJ Treatments Can Help
Dental health
May 21, 2025
The Secret To A Confident Smile: Top Tips For Better Teeth
The Secret To A Confident Smile: Top Tips For Better Teeth
Dental health
May 21, 2025

You Might also Like

autism and language impairment
Specialties

Autism and Language Impairment Share a Genetic Link, But Not All with ASD Have Trouble Speaking

November 4, 2013

Meaningful Use on the Red Carpet

February 26, 2012

IT Strategy for Health Plans: Interview with ikaSystems CEO Joe Marabito

August 11, 2014

Telemedicine Market Shows Strong Growth Due to Healthcare Changes

November 19, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?